# REX AMERICAN RESOURCES Corp: overview

REX · NYSE · CIK 744187 · [Materials](/sectors/materials.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/rex.md) · [Financials](/companies/rex/financials.md) · [Filings](/companies/rex/filings.md) · [Insiders](/companies/rex/insiders.md)

Latest reported revenue: [$168.5m](/filings/0000930413-26-002814.md) for Q2 FY2026, three months to 2026-07-31, from the 10-Q filed Sep 3, 2026 (XBRL us-gaap:Revenues, accession 0000930413-26-002814).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-10-31) | Q4 FY2024 (2025-01-31) | Q1 FY2025 (2025-04-30) | Q2 FY2025 (2025-07-31) | Q3 FY2025 (2025-10-31) | Q4 FY2025 (2026-01-31) | Q1 FY2026 (2026-04-30) | Q2 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [175](/filings/0000930413-25-003566.md) | [158 d](/filings/0000930413-26-000937.md) | [158](/filings/0000930413-26-001786.md) | [159](/filings/0000930413-26-002814.md) | [176](/filings/0000930413-25-003566.md) | [158 d](/filings/0000930413-26-000937.md) | [156](/filings/0000930413-26-001786.md) | [168](/filings/0000930413-26-002814.md) |
| Gross margin | % | [22.7%](/filings/0000930413-25-003566.md) | [11.1% d](/filings/0000930413-26-000937.md) | [9.1%](/filings/0000930413-26-001786.md) | [9.0%](/filings/0000930413-26-002814.md) | [20.6%](/filings/0000930413-25-003566.md) | [38.4% d](/filings/0000930413-26-002814.md) | [18.6%](/filings/0000930413-26-001786.md) | [31.6%](/filings/0000930413-26-002814.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [17.2%](/filings/0000930413-25-003566.md) | [8.9% d](/filings/0000930413-26-000937.md) | [6.7%](/filings/0000930413-26-002814.md) | [5.9%](/filings/0000930413-26-002814.md) | [15.6%](/filings/0000930413-25-003566.md) | [30.1% d](/filings/0000930413-26-000937.md) | [13.9%](/filings/0000930413-26-002814.md) | [24.1%](/filings/0000930413-26-002814.md) |
| Diluted EPS | $ per share | [0.69](/filings/0000930413-25-003566.md) | not reported | [0.26](/filings/0000930413-26-001786.md) | [0.22](/filings/0000930413-26-002814.md) | [0.71](/filings/0000930413-25-003566.md) | not reported | [0.56](/filings/0000930413-26-001786.md) | [1.06](/filings/0000930413-26-002814.md) |
| Free cash flow | $m | [18.2 d](/filings/0000930413-25-003566.md) | [9.2 d](/filings/0000930413-26-000937.md) | [(10.4)](/filings/0000930413-26-001786.md) | [(5.7) d](/filings/0000930413-26-002814.md) | [24.5 d](/filings/0000930413-25-003566.md) | [41.0 d](/filings/0000930413-26-000937.md) | [(13.7)](/filings/0000930413-26-001786.md) | [16.8 d](/filings/0000930413-26-002814.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2022-01-31) | FY2022 (2023-01-31) | FY2023 (2024-01-31) | FY2024 (2025-01-31) | FY2025 (2026-01-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [775](/filings/0000930413-24-001186.md) | [855](/filings/0000930413-25-001069.md) | [833](/filings/0000930413-26-000937.md) | [642](/filings/0000930413-26-000937.md) | [650](/filings/0000930413-26-000937.md) |
| Gross margin | % | [11.7%](/filings/0000930413-24-001186.md) | [5.7%](/filings/0000930413-25-001069.md) | [11.8%](/filings/0000930413-26-000937.md) | [14.2%](/filings/0000930413-26-000937.md) | [19.3%](/filings/0000930413-26-002814.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [6.8%](/filings/0000930413-24-001186.md) | [3.2%](/filings/0000930413-24-001186.md) | [7.3%](/filings/0000930413-24-001186.md) | [11.1%](/filings/0000930413-26-000937.md) | [14.6%](/filings/0000930413-26-000937.md) |
| Diluted EPS | $ per share | [2.92](/filings/0000930413-24-001186.md) | [1.57](/filings/0000930413-25-001069.md) | [1.73](/filings/0000930413-26-000937.md) | [1.65](/filings/0000930413-26-000937.md) | [2.50](/filings/0000930413-26-000937.md) |
| Free cash flow | $m | [86.6](/filings/0000930413-24-001186.md) | [39.2](/filings/0000930413-25-001069.md) | [90.3](/filings/0000930413-26-000937.md) | [(7.1)](/filings/0000930413-26-000937.md) | [49.4](/filings/0000930413-26-000937.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Net income: us-gaap:ProfitLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rex/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $255.6m | 5,662,010 |  | Added +168,584 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $82.4m | 1,825,770 |  | Reduced −70,298 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $71.0m | 1,573,545 |  | Added +120,432 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $65.8m | 1,458,366 |  | Reduced −65,228 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $58.0m | 1,284,806 |  | Added +30,860 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $56.1m | 1,243,606 |  | Added +19,291 |
| [SYSTEMATIC FINANCIAL MANAGEMENT LP](/funds/1085936.md) | 2026-06-30 | $46.8m | 1,036,887 |  | Reduced −71,943 |
| [MANGROVE PARTNERS IM, LLC](/funds/1535392.md) | 2026-06-30 | $45.8m | 1,015,234 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $39.2m | 869,102 |  | Added +33,554 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $29.2m | 646,597 |  | Added +2,702 |

## Recent filings

[All 773 filings](/companies/rex/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-03 | 17:14 ET | [10-Q](/filings/0000930413-26-002814.md) | Quarterly report, period 2026-07-31 | 0000930413-26-002814 |
| 2026-09-02 | 13:44 ET | [8-K](/filings/0000930413-26-002809.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000930413-26-002809 |
| 2026-07-01 | 13:08 ET | [8-K](/filings/0000930413-26-002006.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000930413-26-002006 |
| 2026-06-12 | 14:32 ET | [8-K](/filings/0000930413-26-001847.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000930413-26-001847 |
| 2026-06-03 | 12:59 ET | [8-K](/filings/0000930413-26-001789.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000930413-26-001789 |
| 2026-06-02 | 18:45 ET | [10-Q](/filings/0000930413-26-001786.md) | Quarterly report, period 2026-04-30 | 0000930413-26-001786 |
| 2026-05-28 | 13:08 ET | [8-K](/filings/0000930413-26-001732.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000930413-26-001732 |
| 2026-04-15 | 12:50 ET | [DEF 14A](/filings/0000930413-26-001049.md) | Proxy statement, period 2026-05-28 | 0000930413-26-001049 |
| 2026-03-30 | 20:05 ET | [10-K](/filings/0000930413-26-000937.md) | Annual report, period 2026-01-31 | 0000930413-26-000937 |
| 2026-03-26 | 13:00 ET | [8-K](/filings/0000930413-26-000877.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000930413-26-000877 |

## Latest annual report

[Form 10-K for the fiscal year ended Jan 31, 2026](/filings/0000930413-26-000937.md), filed Mar 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 744187
- Tickers: REX
- Exchange: NYSE
- SIC code: 2860 Industrial Organic Chemicals
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.